TY - JOUR
T1 - Comparison between functional and non-functional adrenocortical carcinoma
AU - Sada, Alaa
AU - Asaad, Malke
AU - Bews, Katherine A.
AU - Thompson, Geoffrey B.
AU - Young, William F.
AU - Bancos, Irina
AU - Farley, David R.
AU - Dy, Benzon M.
AU - Lyden, Melanie L.
AU - Habermann, Elizabeth B.
AU - McKenzie, Travis J.
N1 - Funding Information:
This publication was made possible by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Publisher Copyright:
© 2019
PY - 2020/1
Y1 - 2020/1
N2 - Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6%), II (33%), III (26%), and IV disease (32%); stage was unknown in 3%. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84% of patients with 69% having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95% confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.
AB - Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6%), II (33%), III (26%), and IV disease (32%); stage was unknown in 3%. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84% of patients with 69% having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95% confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=85072271116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072271116&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2019.04.066
DO - 10.1016/j.surg.2019.04.066
M3 - Article
C2 - 31543320
AN - SCOPUS:85072271116
SN - 0039-6060
VL - 167
SP - 216
EP - 223
JO - Surgery (United States)
JF - Surgery (United States)
IS - 1
ER -